BEYOND AIR Reports Earnings Results for FY2024 Q2 Ending September 30 2023

November 21, 2023

🌥️Earnings Overview

On November 13 2023, BEYOND AIR ($NASDAQ:XAIR) reported their financial results for FY2024 Q2 ending September 30 2023. Total revenue for the quarter amounted to USD 0.2 million, a year-on-year increase from 0.0 million. Net income for this period was USD -16.2 million, a greater loss compared to -12.0 million in the same quarter of the prior year.

Share Price

On Monday, BEYOND AIR reported their earnings results for their second fiscal quarter ending September 30th, 2023. Despite these positive growth figures in revenue and earnings, BEYOND AIR’s stock price still dropped. Regardless, BEYOND AIR is still in a strong financial position and is expected to continue to grow in the coming quarters. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Beyond Air. More…

    Total Revenues Net Income Net Margin
    0.3 -63.23 -19593.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Beyond Air. More…

    Operations Investing Financing
    -48.42 1.83 25.14
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Beyond Air. More…

    Total Assets Total Liabilities Book Value Per Share
    58.01 29.17 0.81
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Beyond Air are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -24.6% -22289.9%
    FCF Margin ROE ROA
    -17971.5% -135.7% -71.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has conducted an analysis of BEYOND AIR‘s wellbeing. According to the Star Chart, BEYOND AIR is classified as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. This suggests that BEYOND AIR may be attractive to investors looking to capitalise on a more reliable growth rate. Beyond this, our analysis has found that BEYOND AIR is strong in assets, medium in growth, and weak in dividend, profitability. This indicates that whilst BEYOND AIR may not be the most lucrative option for investors seeking short-term returns, it could provide an attractive option for those with a longer-term outlook. Finally, BEYOND AIR has an intermediate health score of 4/10 considering its cashflows and debt. This suggests that BEYOND AIR might be able to sustain future operations in times of crisis. Taken together, this presents BEYOND AIR as a potentially attractive option for investors seeking reliable, long-term gains. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition in the pulmonary and sleep apnea market is heating up as Beyond Air Inc, Lucid Diagnostics Inc, Motus GI Holdings Inc, and CVRx Inc battle for market share. Lucid Diagnostics Inc is a leading provider of sleep diagnostic services. Motus GI Holdings Inc is a provider of endoscopy products and services. CVRx Inc is a leading provider of cardiovascular devices.

    – Lucid Diagnostics Inc ($NASDAQ:LUCD)

    Lucid Diagnostics Inc is a medical technology company that develops and commercializes diagnostic tests for infectious diseases. The company’s flagship product is the Lucid-Dx platform, a point-of-care diagnostics system that can detect a range of infectious diseases within minutes. Lucid Diagnostics Inc has a market cap of 73.67M as of 2022. The company’s return on equity was -102.87% for the year ending December 31, 2021. Lucid Diagnostics Inc is a publicly traded company on the Nasdaq Stock Market under the ticker symbol LDX.

    – Motus GI Holdings Inc ($NASDAQ:MOTS)

    Motus GI Holdings Inc is a medical technology company that develops, manufactures and markets endoscopy products designed to improve clinical outcomes and lower healthcare costs. The company’s market cap is $6.61M as of 2022 and its ROE is -183.03%. Motus GI’s products are used by gastroenterologists and other physicians to diagnose and treat gastrointestinal disorders.

    – CVRx Inc ($NASDAQ:CVRX)

    The company’s market capitalization is $248.04 million and its ROE is -20.86%. The company is a provider of digital video recording (DVR) solutions for the pay-TV industry. The company’s solutions enable pay-TV operators to offer their subscribers a range of services, including time-shifted TV, on-demand TV, and nDVR (network-based DVR).


    Investors may want to consider the recent performance of BEYOND AIR, as the company reported a total revenue of USD 0.2 million for the second quarter of FY2024, a significant increase from the same period last year. However, the reported net income of -16.2 million was slightly lower than last year’s total of -12.0 million. While this may be concerning to some investors, it is important to take into account the company’s long-term potential and overall financial health before making any decisions.

    Recent Posts

    Leave a Comment